Evidence map›Paper›PMID 41572489›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Cancer-Like Fragmentomic Characteristics of Somatic Variants in Cell-Free DNA.

Zhenyu Zhang, Yunyun An, Mengqi Yang, Yuqi Pan, Xiaoyi Liu, Fanglei Gong, Huizhen Lin, Bianbian Tang, Yunxia Bai, Xin Zhao and 3 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zhenyu ZhangInstitute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, China.
Yunyun AnInstitute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, China.
Mengqi YangInstitute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, China.
Yuqi PanInstitute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, China.
Xiaoyi LiuInstitute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, China.
Fanglei GongInstitute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, China.
Huizhen LinInstitute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, China.
Bianbian TangInstitute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, China.
Yunxia BaiInstitute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, China.
Xin ZhaoHepato-Biliary Surgery Division, Shenzhen Third People's Hospital, The Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, China.
Yu ZhaoMolecular Cancer Research Center, School of Medicine, Shenzhen Campus of Sun Yat-sen University, Sun Yat-sen University, Shenzhen, China.
Changzheng DuCancer Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
Kun SunInstitute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, China.ORCID https://orcid.org/0000-0002-9883-1616

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2023B1515120073National Key R&D Program of China 2022YFA0912700National Natural Science Foundation of China 32401206Shenzhen Bay Scholar FellowshipShenzhen Clinical Research Center for Oral Diseases 20210617170745001
6 · The paper itself

Abstract

Cell-free DNA (cfDNA) in plasma consists of short DNA fragments resulting from a non-random fragmentation process, with distinct fragmentomic characteristics that are related with their cellular origins. Here, we report that somatic variant signatures in cfDNA markedly differ between non-cancerous controls and cancer patients, indicating that tumor-associated signals are retained in these variants. Surprisingly, even in controls, cfDNA molecules harboring somatic variants exhibit cancer-like fragmentomic characteristics, such as reduced size, decreased DNA methylation, and altered end motif usages and distributions in the nucleosome structure. Further investigations suggest that such cancer-like traits are associated with somatic variants derived from clonal hematopoiesis. Importantly, these somatic variants-associated fragmentomic aberrations are more pronounced in cancer patients, enabling cancer diagnosis. In a large pan-cancer cohort, we utilize AI to integrate genomic, fragmentomic, and epigenomic features to develop diagnostic models named FreeSV and FreeSV+. Leveraging somatic variant-associated features alone, the FreeSV model achieved area under the ROC curves (AUCs) between 0.81-0.92 across cancer types; however, when genomewide features are also included, the AUCs of FreeSV+ model substantially increased to 0.93-0.99 across cancer types, highlighting the significance of integrative genomic and fragmentomic analyses in cfDNA for cancer liquid biopsy.

Indexed as

Biomarkers, TumorCell-Free Nucleic AcidsNeoplasmsDNA MethylationHumansBiomarkers, TumorCell-Free Nucleic Acidsartificial intelligencecancer diagnosisend motifepigenomicsliquid biopsy

Identifiers

PMID41572489
PMCPMC13042374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.